BC3402 + IMFINZI
Hepatocellular Carcinoma (HCC)
Phase 1b/2Collaboration with AstraZeneca, first patient dosed (2023)
Key Facts
Indication
Hepatocellular Carcinoma (HCC)
Phase
Phase 1b/2
Status
Collaboration with AstraZeneca, first patient dosed (2023)
Company
About BioCity Biopharma
A clinical-stage biopharma developing novel BIC/FIC therapeutics for oncology and nephrology, with a multi-modality pipeline and global clinical operations.
View full company profileTherapeutic Areas
Other Hepatocellular Carcinoma (HCC) Drugs
| Drug | Company | Phase |
|---|---|---|
| ADI-PEG 20 (pegargiminase) | Polaris Pharma | Phase 2/3 |
| Fostroxacitabine bralpamide (MIV-818) | Medivir | Phase 2a |
| Nelitolimod (SD-101) via PEDD™ + systemic checkpoint inhibitors | TriSalus Life Sciences | Phase 1/2 |
| YntraDose | BetaGlue Therapeutics | Pre-clinical |
| seRNA 001 | SRTD biotech | Preclinical |
| Seravue® (Diagnostic Assay) | ImCare Biotech | Development |
| ZW251 | Zymeworks | Phase 1 |
| TTI-101 | Tvardi Therapeutics | Phase 1b/2 |